FDA lifts clinical hold on Rocket's gene therapy for heart failure after 3-month delay
New Jersey’s Rocket Pharmaceuticals hit a major roadblock for its AAV-delivered gene therapy for heart failure in May after the FDA came asking for more details on target patients. Three months down the road, Rocket is clear for liftoff once again.
The FDA on Monday lifted its clinical hold on Rocket’s Phase I trial for gene therapy candidate RP-A501 for Danon disease, an ultra-rare genetic disorder that can lead to heart failure in children and young adults, the company said in a release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.